MiRNA-15a/-16靶向调控PHF19基因对多发性骨髓瘤细胞增殖和耐药的影响及机制研究

批准号:
81400174
项目类别:
青年科学基金项目
资助金额:
23.0 万元
负责人:
郝牧
依托单位:
学科分类:
H0810.淋巴瘤与淋巴细胞疾病
结题年份:
2017
批准年份:
2014
项目状态:
已结题
项目参与者:
杨烨、邹德慧、李长虹、藏美蓉、杜星晨
国基评审专家1V1指导 中标率高出同行96.8%
结合最新热点,提供专业选题建议
深度指导申报书撰写,确保创新可行
指导项目中标800+,快速提高中标率
微信扫码咨询
中文摘要
MM依然是一种不可治愈的恶性肿瘤,耐药是导致复发的重要原因。探明MM复发、耐药的分子机制,对提高MM疗效具有重要意义。课题组前期对MM患者细胞序贯基因表达谱分析发现PHF19在治疗后及复发时肿瘤耐药克隆中表达明显增高并具有临床预后意义。并且证实miRNA-15a/-16靶向调控PHF19表达,上调miRNA-15a/-16表达可抑制MM细胞增殖、提高药物敏感性。据此我们提出MM细胞低表达miRNA-15a/-16导致其靶基因PHF19表达增加,促进MM细胞增殖与耐药,导致患者生存期缩短,预后不良的科学假设。本研究拟从基因、蛋白水平,体外及体内实验等多层次探讨miRNA-15a/-16靶向调控PHF19以及PHF19促进MM细胞增殖和耐药的分子机制。并结合ChIP-seq等高通量检测方法,探明PHF19作用的关键信号通路及调控分子和表观遗传学修饰信息,为寻找新的治疗靶点提供理论及实验基础。
英文摘要
Although major progress has been made in the treatment of MM with an increase in median survival from 2.5 to 10 years over the last two decades, the large majority of the patients still relapse and ultimately die of their disease. This is due to the persistence of a drug-resistant subpopulation of MM cells even after intensive therapy with tandem autologous transplants and prolonged maintenance with the newer drugs. To achieve a cure for MM, a better understanding of the genetic makeup of these drug-resistant MM cells is required so that these cells can be specifically targeted. Our previous study of sequential analysis of gene expression profiles (GEP) of tumor cells in MM patients showed that PHF19 expression was significantly up-regulated in resistant tumor cell clones of pre-1st ASCT and relapse MM patients. Kaplan-Meier analyses showed that MM patients with higher expression of PHF19 had a significantly inferior PFS and OS. Our preliminary results also demonstrated that miRNA-15a/-16 had lower expression in MM cells. Dual luciferase reporter assay indicated that PHF19 was the target gene of miRNA-15a/-16. Up-regulation of miRNA-15a/-16 suppressed MM cells proliferation and promoted drug induced apoptosis. It is our hypothesis that PHF19 as a target gene of miRNA-15a/-16 promotes MM cells proliferation and drug-resistance. Therefore, this project will investigate the miRNA-15a/-16 mediates PHF19 functions of cell proliferation and drug resistance in MM. Combined with ChIP-seq and microarray high-throughput assay, Co-IP experiments, as well as 5TGM1 mouse MM model, the PHF19 key signaling pathways and the role of regulatory molecules and epigenetic modification of information will be clarified. The results will provide theoretical and experimental foundation for the search for new therapeutic targets in MM.
MM依然是一种不可治愈的恶性肿瘤,耐药是导致复发的重要原因。探明MM复发、耐药的分子机制,对提高MM疗效具有重要意义。课题组前期对临床MM患者细胞序贯基因表达谱分析发现PHF19在治疗后及复发时肿瘤耐药克隆中表达明显增高并具有临床预后意义。生物信息学分析提示miRNA-15a/-16靶向调控PHF19表达,上调miRNA-15a/-16表达可抑制MM细胞增殖、提高药物敏感性。据此我们提出MM细胞低表达miRNA-15a/-16导致其靶基因PHF19表达增加,促进MM细胞增殖与耐药,导致患者生存期缩短,预后不良的科学假设。本研究首先应用双荧光素酶报告基因系统证实miR-15a与PHF19基因 3’UTR区直接结合,降解PHF19 mRNA,从而抑制其mRNA合成及蛋白翻译,MM细胞低表达miR-15a是导致其PHF19表达升高的重要原因。为了阐明PHF19在介导MM细胞增殖存活、耐药中的作用机制,应用慢病毒感染系统制备PHF19过表达的MM细胞系,体外增殖曲线、软琼脂克隆形成实验及流式细胞术检测显示PHF19过表达后MM细胞增殖速度加快、克隆形成能力增强,对万坷、多柔比星、依托泊甙等化疗药物敏感性降低。利用NOD/SCID小鼠模型,也证实PHF19过表达MM细胞体内增殖能力明显加强,对万坷等药物治疗耐药,PHF19过表达组小鼠生存时间明显缩短。采用条件性诱导敲除PHF19表达后,细胞增殖明显受抑、对化疗药物敏感性增加,且小鼠生存期得到延长。进一步采用TAP/MASS、CoIP、RNAseq、Western Blot等技术研究发现PHF19可与EZH2/AKT等蛋白结合,促进磷酸化EZH2水平,使其H3K27甲基化酶活性降低,因此PHF19过表达细胞中H3K27me3水平降低,促进HIF1a、IGF1等蛋白表达上升,从而促进并介导MM细胞增殖加快及耐药的产生。抑制PHF19表达可逆转MM细胞增殖加快及耐药的产生。本研究从基因、蛋白水平,体外及体内实验等多层次阐明miRNA-15a靶向调控PHF19以及PHF19促进MM细胞增殖和耐药的分子机制。为开发以PHF19为治疗靶点的新的治疗策略提供理论及实验基础。
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
Detection of recurrent cytogenetic aberrations in multiple myeloma: a comparison between MLPA and iFISH.
多发性骨髓瘤复发性细胞遗传学畸变的检测:MLPA 与 iFISH 的比较
DOI:10.18632/oncotarget.5371
发表时间:2015-10-27
期刊:Oncotarget
影响因子:--
作者:Zang M;Zou D;Yu Z;Li F;Yi S;Ai X;Qin X;Feng X;Zhou W;Xu Y;Li Z;Hao M;Sui W;Deng S;Acharya C;Zhao Y;Ru K;Qiu L;An G
通讯作者:An G
Low serum miR-19a expression as a novel poor prognostic indicator in multiple myeloma.
低血清 miR-19a 表达作为多发性骨髓瘤的新型不良预后指标
DOI:10.1002/ijc.29199
发表时间:2015-04-15
期刊:INTERNATIONAL JOURNAL OF CANCER
影响因子:6.4
作者:Hao, Mu;Zang, Meirong;Wendlandt, Erik;Xu, Yan;An, Gang;Gong, Dasen;Li, Fei;Qi, Fang;Zhang, Yanru;Yang, Ye;Zhan, Fenghuang;Qiu, Lugui
通讯作者:Qiu, Lugui
MicroRNA-15a/16-1 cluster located at chromosome 13q14 is down-regulated but displays different expression pattern and prognostic significance in multiple myeloma.
位于染色体 13q14 的 MicroRNA-15a/16-1 簇下调,但在多发性骨髓瘤中表现出不同的表达模式和预后意义
DOI:10.18632/oncotarget.5681
发表时间:2015-11-10
期刊:Oncotarget
影响因子:--
作者:Li F;Xu Y;Deng S;Li Z;Zou D;Yi S;Sui W;Hao M;Qiu L
通讯作者:Qiu L
Serum high expression of miR-214 and miR-135b as novel predictor for myeloma bone disease development and prognosis.
miR-214和miR-135b的血清高表达作为骨髓瘤骨病发展和预后的新预测因子
DOI:10.18632/oncotarget.7319
发表时间:2016-04-12
期刊:Oncotarget
影响因子:--
作者:Hao M;Zang M;Zhao L;Deng S;Xu Y;Qi F;An G;Qin Y;Sui W;Li F;Yang W;Li Z;Yi S;Zou D;Zhan F;Qiu L
通讯作者:Qiu L
DOI:10.18632/oncotarget.5681.
发表时间:2015
期刊:oncotarget
影响因子:--
作者:Li Fei;Xu Yan;Deng Shuhui;Li Zengjun;Zou Dehui;Yi Shuhua;Sui Weiwei;Hao Mu;Qiu Lugui
通讯作者:Qiu Lugui
TAp73/DNp73表达失衡在多发性骨髓瘤DNA损伤诱导细胞凋亡中的作用及机制研究
- 批准号:81570181
- 项目类别:面上项目
- 资助金额:60.0万元
- 批准年份:2015
- 负责人:郝牧
- 依托单位:
国内基金
海外基金
